Investors 2017-08-18T12:57:17+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

ASX Announcement – 2017 Annual Report

The 2017 Dimerix Annual Report is now available here

ASX Announcement – WA Broker Meets Biotech presentation

Dimerix CEO Kathy Harrison is pleased to be speaking alongside a great collection of other biotech companies at the Western Australian AusBiotech Broker Meets Biotech event today. Date: Wednesday 13 September 2017 Time: 1:00pm arrival for a [...]

ASX Announcement – Notice of security consolidation

Dimerix has announced a proposed consolidation of DXB shares. Full details of the notification are available here.

ASX Announcement – Notice of AGM

Dimerix will hold it's Annual General Meeting on 19 October 2017 at 10.00 WST in West Perth, WA. Full details of the meeting are available here. NOTE: An earlier version of the Notice of AGM [...]

Read More

Media Coverage

Dimerix in the news following positive Phase 2a trial results in Chronic Kidney Disease

As you may know, Dimerix was pleased to release positive results for our DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) on 12 July 2017. You can see that announcement here. Following the data [...]

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

NDF Research: An update report on Dimerix

View the update analyst report on their website.

The Australian: “Trial results ‘exciting’ for biotech Dimerix”

Dimerix CEO Kathy Harrison interviewed by The Australian Read the article on their website.

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates